SION

Company Overview — What Does Sionna Therapeutics, Inc. Do?

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts. Sionna Therapeutics, Inc. (SION) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael Cloonan and employs approximately 35 people, headquartered in WALTHAM, Massachusetts. With a market capitalization of $1.9B, SION is one of the notable companies in the Healthcare sector.

Sionna Therapeutics, Inc. (SION) Stock Rating — Hold (April 2026)

As of April 2026, Sionna Therapeutics, Inc. receives a Hold rating with a composite score of 35.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.SION ranks #874 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Sionna Therapeutics, Inc. ranks #61 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SION Stock Price and 52-Week Range

Sionna Therapeutics, Inc. (SION) currently trades at $38.89. The 52-week high for SION is $45.00, which means the stock is currently trading -13.6% from its annual peak. The 52-week low is $7.25, putting the stock 436.0% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is SION Overvalued or Undervalued? — Valuation Analysis

Sionna Therapeutics, Inc. (SION) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.39x, versus the sector average of 2.75x.

At current multiples, Sionna Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Sionna Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Sionna Therapeutics, Inc. (SION) earns a quality factor score of 28/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -98.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -92.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SION Debt, Balance Sheet, and Financial Health

Sionna Therapeutics, Inc. has a debt-to-equity ratio of 6.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 20.61x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $51M.

SION has a beta of 0.94, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Sionna Therapeutics, Inc. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Sionna Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Sionna Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.88. Net income for the quarter was $-75M. Operating income came in at $-89M.

In FY 2025, Sionna Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.88. Net income for the quarter was $-75M. Operating income came in at $-89M.

In Q3 2025, Sionna Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.46. Net income for the quarter was $-20M. Operating income came in at $-24M.

In Q2 2025, Sionna Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-410.00. Net income for the quarter was $-18M. Operating income came in at $-22M.

Over the past 5 quarters, Sionna Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing SION stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SION Dividend Yield and Income Analysis

Sionna Therapeutics, Inc. (SION) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SION Momentum and Technical Analysis Profile

Sionna Therapeutics, Inc. (SION) has a momentum factor score of 67/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 1/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

SION vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Sionna Therapeutics, Inc. (SION) ranks #61 out of 838 stocks based on the Blank Capital composite score. This places SION in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SION against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SION vs S&P 500 (SPY) comparison to assess how Sionna Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

SION Next Earnings Date

No upcoming earnings date has been announced for Sionna Therapeutics, Inc. (SION) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SION? — Investment Thesis Summary

Sionna Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 28/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Price momentum is positive at 67/100, suggesting the trend favors buyers. High volatility (stability score 35/100) increases portfolio risk.

In summary, Sionna Therapeutics, Inc. (SION) earns a Hold rating with a composite score of 35.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SION stock.

Related Resources for SION Investors

Explore more research and tools: SION vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SION head-to-head with peers: SION vs AZN, SION vs SLGL, SION vs VMD.